 |
 |
|
|
RESÚMENES FEBRERO 2005 |
Psychotic Disorders & Antipsychotics
(Requiere estar conectado a internet. Haga un click en la
información del journal)
Lorazepam and diazepam rapidly relieve catatonic
signs in patients with schizophrenia
TIAO-LAI HUANG
Psychiatry and Clinical Neurosciences Volume
59 Issue 1 Page 52 - February 2005
Miriam G.
Brunstein, Eduardo S. Ghisolfi, Fernanda L. P. Ramos; and Diogo R. Lara
J Clin Psychiatry 2005;66:213-219
Histamine
H1 receptors in schizophrenic patients measured by positron emission
tomography
Kentaro Iwabuchi,
Chihiro Ito, Manabu Tashiro, Motohisa Kato, Michiko Kano, Masatoshi Itoh, Ren
Iwata, Hiroo Matsuoka, Mitsumoto Sato and Kazuhiko Yanai
European Neuropsychopharmacology. Volume 15, Issue 2,
March 2005, Pages 185-191
Pharmacogenetics
of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor
polymorphisms separately associate with positive and negative symptom response
Gavin P. Reynolds,
ZhiJian Yao, XiaoBin Zhang, Jing Sun and ZhiJun Zhang
European Neuropsychopharmacology. Volume 15, Issue 2,
March 2005, Pages 143-151
Mari Murashita,
Ichiro Kusumi, Takeshi Inoue, Yoshito Takahashi, Hiroshi Hosoda, Kenji Kangawa
and Tsukasa Koyama
Psychoneuroendocrinology. Volume 30, Issue 1, January
2005, Pages 106-110
Alissa Pencer, Jean
Addington and Donald Addington
Psychiatry Research. Volume 133, Issue 1, 30 January
2005, Pages 35-43
R. Manchanda, R. Norman, A. Malla, R. Harricharan,
J. Takhar, S. Northcott
Acta Psychiatrica Scandinavica. Volume 111 Issue
3 Page 208 - March 2005
Duration of untreated psychosis and outcome in first-episode psychosis.
Perspective from a developing country
P. Oosthuizen, R. A. Emsley, N. Keyter, D. J. H.
Niehaus, L. Koen
Acta Psychiatrica Scandinavica. Volume 111 Issue
3 Page 214 - March 2005
Effectiveness of antipsychotic treatment for schizophrenia: 6-month
results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO)
study
J. M. Haro, E. T. Edgell, D. Novick, J. Alonso, L.
Kennedy, P. B. Jones, M. Ratcliffe, A. Breier on behalf of the SOHO advisory
board
Acta Psychiatrica Scandinavica. Volume 111 Issue
3 Page 220 - March 2005
Olanzapine vs. other antipsychotics in actual out-patient settings: six
months tolerability results from the European Schizophrenia Out-patient Health
Outcomes study
M. Lambert, J. M. Haro, D. Novick, E. T. Edgell, L.
Kennedy, M. Ratcliffe, D. Naber
Acta Psychiatrica Scandinavica. Volume 111 Issue
3 Page 232 - March 2005
Cerebral metabolic changes induced by clozapine in schizophrenia and
related to clinical improvement
Vicente Molina,
Juan D. Gispert, Santiago Reig, Javier Sanz,
Javier Pascau, Andrés Santos, Manuel Desco and Tomás Palomo
Psychopharmacology 2005; Volume 178, Number 1: 17
- 26
Prolactin levels in male schizophrenic patients treated with risperidone
and haloperidol: a double-blind and randomized study
Xiang Yang Zhang,
Dong Feng Zhou, Lian Yuan Cao, Pei Yan Zhang,
Gui Ying Wu and Yu Cun Shen
Psychopharmacology 2005; Volume 178, Number 1: 35
- 40
Therapeutic drug
monitoring of patients on risperidone depot
Ragnar Nesvåg and Lars
Tanum
Nordic Journal of Psychiatry. Volume 59, Number 1 /
March 2005: 51 - 55
Theories
of schizophrenia: a genetic-inflammatory-vascular synthesis
Daniel
R. Hanson and Irving I. Gottesman
BMC Medical Genetics 2005, 6:7;
11 February 2005
Pharmacokinetics
and D2 receptor occupancy of long-acting injectable risperidone (Risperdal
Consta™) in patients with schizophrenia
Ola Gefvert,
Bo Eriksson, Per Persson, Lars Helldin, Annika Björner,
Erik Mannaert, Bart Remmerie, Mariëlle Eerdekens and
Svante Nyberg
The International Journal of Neuropsychopharmacology
(2005), 8:1:27-36
Estrogen as an
adjuvant therapy to antipsychotics does not prevent relapse in women suffering
from schizophrenia: results of a placebo-controlled double-blind study
Niels Bergemann,
Christoph Mundt, Peter Parzer, Manoshi Pakrasi, Ursula Eckstein-Mannsperger,
Susanne Haisch, Birgit Salbach, Klaus Klinga, Benno Runnebaum and Franz Resch
Schizophrenia Research. Volume 74, Issues 2-3, 1 May
2005, Pages 125-134
A double blind
study showing that two weeks of daily repetitive TMS over the left or right
temporoparietal cortex reduces symptoms in patients with schizophrenia who are
having treatment-refractory auditory hallucinations
Seung-Hwan Lee, Won
Kim, Young-Cho Chung, Kyung-Hee Jung, Won-Myong Bahk, Tae-Yun Jun, Kwang-Soo
Kim, Mark S. George and Jeong-Ho Chae
Neuroscience Letters. Volume 376, Issue 3, 16 March
2005, Pages 177-181
A comparison of
olanzapine versus risperidone for the treatment of schizophrenia: a
meta-analysis of randomised clinical trials
Mia A. C. Mudge, Peter J.
Davey, Dr Kristina A. Coleman, William Montgomery, Victoria S. Croker, Karen
Mullen, David J. Castle
International Journal of Psychiatry in Clinical
Practice. Volume 9, Number 1 / March 2005: 3 - 15
Efficacy, safety
and tolerability of quetiapine: short-term high doses with long-term follow-up
Judit Nagy
International Journal of Psychiatry in Clinical
Practice. Volume 9, Number 1 / March 2005: 16 - 21
Treatment in risperidone-induced amenorrhoea
Bun-Hee Lee, Chang-Su Han,
Kye-Hyun Kim, Yong-Ku Kim
International Journal of Psychiatry in Clinical
Practice. Volume 9, Number 1 / March 2005:29 - 34
Attitudes to
atypical and conventional antipsychotic drug treatment in clinicians
participating in the cutlass study
Helen M. Lloyd, Alison J.
Markwick, Eleanor R. Page, Shôn Lewis, Thomas R.E. Barnes
International Journal of Psychiatry in Clinical
Practice. Volume 9, Number 1 / March 2005 :35 - 40
Robin G. McCreadie,
Tirupati N. Srinivasan, Raman Padmavati and Rangaswamy Tharac
Journal of Psychiatric Research. Volume 39, Issue 3,
May 2005, Pages 261-266
Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic drugs
David Taylor, Corina Young, Radia Mohamed, Carol Paton, Rebecca Walwyn
Journal
of Psychopharmacology, Vol. 19, No. 2, 182-186 (2005)
Prediction of response to risperidone treatment with respect to plasma
concencentrations of risperidone, catecholamine metabolites, and polymorphism
of cytochrome P450 2D6 Kakihara, Shingo; Yoshimura,
Reiji; Shinkai, Koji; Matsumoto, Chima; Goto, Makiko; Kaji, Kyoko; Yamada,
Yasuhisa; Ueda, Nobuhisa; Ohmori, Osamu; Nakamura, Jun
International Clinical Psychopharmacology.
20(2):71-78, March 2005
Risperidone for pre-existing severe tardive dyskinesia: a 48-week
prospective follow-up study
Bai, Ya-Mei; Yu, Shun-Chieh; Chen, Jen-Yeu; Lin,
Chih-Yuan; Chou, Pesus; Lin, Chao-Cheng
International Clinical Psychopharmacology.
20(2):79-85, March 2005
The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist,
on olanzapine-induced weight gain in first-episode schizophrenia patients
Poyurovsky, Michael; Pashinian, Artashes;
Levi, Aya; Weizman, Ronit; Weizman, Abraham
International Clinical Psychopharmacology.
20(2):101-103, March 2005